Alzheimer's Disease
Conditions
Brief summary
This study is to evaluate of Exploratory Efficacy of NEUROSTEM® in Subjects who control group of NEUROSTEM® Phase-I/IIa Clinical Trial
Interventions
High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
Sponsors
Medipost Co Ltd.
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects who have been treated with placebo in phase 1/2a clinical trial of NEUROSTEM® 2. Subjects who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial (in case it is difficult for the participant to sign, the consent of the legal representative)
Exclusion criteria
1. History of stroke within 3 months prior to study enrollment 2. Severe liver disorder (equivalent to double the normal values of ALT and AST) at Visit 1 3. Severe kidney disorder (serum creatinine ≥1.5mg/dL) at Visit 1 4. Abnormal Laboratory findings at Visit 1 * Hemoglobin \< 9.5 g/dL for male and \<9.0 g/dL for female * Total WBC Count \< 3000/mm3 * Total Bilirubin \>= 3 mg/dL 5. Suspected active lung disease based on chest X-ray at Visit 1 6. Bleeding disorder (abnormal blood coagulation test result (i.e. platelet count of \< 137,000/mm3, PT ≥ 1.5 INR, or aPTT ≥ 1.5 x control anti-coagulant or anti-platelet, without anticoagulant or anti-platelet therapy) 7. Diagnosis of cancer (of any body system, including brain tumor) 8. Contraindicated for any of the tests performed during the clinical trial period (for example, MRI, CT, PET) 9. Whom the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from the baseline in ADAS-Cog | 4weeks,8weeks,12weeks,24 weeks after the first dose | The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis using an 11-point AD Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from the baseline in K-MMSE(korean version) | 24 weeks after the first dose | The MMSE(Mini-Mental State Examination) is a brief, practical test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score from 0 to 30, with higher scores indicating better function |
| Change from the baseline in CGA-NPI | 24 weeks after the first dose | Caregiver-administered Neuropsychiatric Inventory, Measure abnormal behavior. The score range is 0-144. A higher score means severe abnormal behavior. |
| Change from the baseline in SIB | 24 weeks after the first dose | The Severe Impairment Battery (SIB) is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best) |
| Change in CDR-SOB | 24 weeks after the first dose | The CDR-SOB(Clinical Dementia Rating, Sum of Boxes) is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment. |
| Change in CIBIC-plus | 24 weeks after the first dose | The Clinician's Interview-Based Impression of Change-plus(CIBIC-plus) is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening). |
| Change from the baseline in CSF biomarkers | 24 weeks after the first dose | biomakrers analysis (Amyloid beta 42, Phosphorylated tau, Total tau, RBC, WBC, Protein, Glucose) |
| ADAS-Cog Response Rate | The ADAS-cog response is defined as no worsening (no change or improvement on ADAS-cog score) of the ADAS-cog score at 24 weeks after the first administration compared to the baseline | Alzheimer's Disease assessment Scale-Cognitive Subscale |
Countries
South Korea
Contacts
Primary ContactHeejin kim, MD
Outcome results
None listed